Showing results (491-500 of 1,063) with videos related to
Sort By:
Pageof 107
Alzheimer'S & Dementia (New York, N. Y.)|February 23, 2024
Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer's diseaseStefan J Teipel, Anna G M Temp, Michael W LutzAlzheimer'S & Dementia (New York, N. Y.)|June 5, 2024
Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modelingXiaoxiao Zhou, Haotian Zou, Michael W Lutz, et al.Alzheimer'S & Dementia (New York, N. Y.)|April 23, 2024
Genetic and multi-omic risk assessment of Alzheimer's disease implicates core associated biological domainsGregory A Cary, Jesse C Wiley, Jake Gockley, et al.Alzheimer'S & Dementia (New York, N. Y.)|May 24, 2024
Genetic associations with psychosis and affective disturbance in Alzheimer's diseaseInga Margret Antonsdottir, Byron Creese, Lambertus Klei, et al.Alzheimer'S & Dementia (New York, N. Y.)|November 9, 2023
Cognitive decline assessment in speakers of understudied languagesOula Hatahet, Florian Roser, Mohamed L SeghierAlzheimer'S & Dementia (New York, N. Y.)|October 13, 2023
A randomized, double-blind, placebo-controlled, parallel-group 12-week pilot phase II trial of SaiLuoTong (SLT) for cognitive function in older adults with mild cognitive impairmentGenevieve Z Steiner-Lim, Alan Bensoussan, Elana R Andrews-Marney, et al.Alzheimer'S & Dementia (New York, N. Y.)|October 3, 2023
Targeting immunometabolic pathways for combination therapy in Alzheimer's diseaseJennifer Erichsen, Suzanne CraftAlzheimer'S & Dementia (New York, N. Y.)|September 28, 2023
PDE5 inhibitor drugs for use in dementiaAtticus H Hainsworth, Ottavio Arancio, Fanny M Elahi, et al.Alzheimer'S & Dementia (New York, N. Y.)|September 24, 2024
Assessing social connection for long-term care home residents: A scoping review of measure contentMadalena P Liougas, Andrew Sommerlad, Hannah M O'Rourke, et al.Pageof 107